Honest reviews of 89+ online health providers across GLP-1 weight loss, TRT, ED, hair loss, women's health, longevity, peptides, and primary care. Compare pricing, clinical oversight, and real patient experiences.
A major cardiovascular event occurred in 6.5% of the semaglutide group and 8.0% of the placebo group (hazard ratio, 0.80).
17,604 adults aged 45 or older with established cardiovascular disease, BMI of at least 27, and no diabetes; Mean follow-up of 39.8 months. Read the linked peer-reviewed source for the full methodology, findings, and limitations.
Lincoff et al., NEJM 2023 · SELECT